Anna K. Dewan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anna K. Dewan has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Ai-Tram N. Bui
Department of Dermatology, The Center for Cutaneous Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts
2 shared publications - Ajit Johnson Nirmal
Laboratory of Systems Pharmacology, Harvard Medical School, Boston, USA
2 shared publications Alan Boyd
2 shared publications- Christine Guo Lian
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
2 shared publications - Daniel Y. Kim
Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, USA
2 shared publications Deanna Dickerman
2 shared publications
Latest Publications
- 13 February 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (8) , 1887-1890.e5
Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade Using Tissue Cyclic Immunofluorescence: A Pilot Study
- 13 February 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (8) , 1887-1890.e5
Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade Using Tissue Cyclic Immunofluorescence: A Pilot Study
- Open Access
Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic Immunofluorescence
In this study, we demonstrate the utility of whole-slide CyCIF (tissue-based cyclic immunofluorescence) imaging for characterizing immune cell infiltrates in immune checkpoint inhibitor (ICI)-induced dermatologic adverse events (dAEs). We analyzed six cases of ICI-induced dAEs, including lichenoid, bullous pemphigoid, psoriasis, and eczematous eruptions, comparing immune profiling results obtained using both standard immunohistochemistry (IHC) and CyCIF. Our findings indicate that CyCIF provides more detailed and precise single-cell characterization of immune cell infiltrates than IHC, which relies on semi-quantitative scoring by pathologists. This pilot study highlights the potential of CyCIF to advance our understanding of the immune environment in dAEs by revealing tissue-level spatial patterns of immune cell infiltrates, allowing for more precise phenotypic distinctions and deeper exploration of disease mechanisms. By demonstrating that CyCIF can be performed on friable tissues, such as bullous pemphigoid, we provide a foundation for future studies to examine the drivers of specific dAEs using larger cohorts of phenotyped toxicity and suggest a broader role for highly multiplexed tissue imaging in phenotyping the immune mediated disease that they resemble.
Open AccessImmune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic Immunofluorescence
In this study, we demonstrate the utility of whole-slide CyCIF (tissue-based cyclic immunofluorescence) imaging for characterizing immune cell infiltrates in immune checkpoint inhibitor (ICI)-induced dermatologic adverse events (dAEs). We analyzed six cases of ICI-induced dAEs, including lichenoid, bullous pemphigoid, psoriasis, and eczematous eruptions, comparing immune profiling results obtained using both standard immunohistochemistry (IHC) and CyCIF. Our findings indicate that CyCIF provides more detailed and precise single-cell characterization of immune cell infiltrates than IHC, which relies on semi-quantitative scoring by pathologists. This pilot study highlights the potential of CyCIF to advance our understanding of the immune environment in dAEs by revealing tissue-level spatial patterns of immune cell infiltrates, allowing for more precise phenotypic distinctions and deeper exploration of disease mechanisms. By demonstrating that CyCIF can be performed on friable tissues, such as bullous pemphigoid, we provide a foundation for future studies to examine the drivers of specific dAEs using larger cohorts of phenotyped toxicity and suggest a broader role for highly multiplexed tissue imaging in phenotyping the immune mediated disease that they resemble.
- 10 February 2022
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 51 (3) , 252-254
A temporal cluster of cutaneous drug eruptions developing after initiation of hydroxychloroquine
Herein, we report three cases of cutaneous drug eruptions developing 2 weeks after initiation of hydroxychloroquine (HCQ). Two patients developed morbilliform eruptions, and one patient developed d...
- 10 February 2022
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 51 (3) , 252-254
A temporal cluster of cutaneous drug eruptions developing after initiation of hydroxychloroquine
Herein, we report three cases of cutaneous drug eruptions developing 2 weeks after initiation of hydroxychloroquine (HCQ). Two patients developed morbilliform eruptions, and one patient developed d...
- 18 October 2018
- Published by Wiley in Pediatric Dermatology
- Vol. 36 (1) , E46-E47
In utero development of epidermolysis bullosa acquisita
We report the case of an infant born with perioral vesicles that rapidly spread to involve his mouth and the majority of his body. Histopathology, immunofluorescence, and enzyme‐linked immunohistochemistry assays confirmed a diagnosis of epidermolysis bullosa acquisita (EBA). His mother had no history of EBA, and serum indirect immunofluorescence was negative. The patient improved rapidly with local wound care and oral dapsone.
- 18 October 2018
- Published by Wiley in Pediatric Dermatology
- Vol. 36 (1) , E46-E47
In utero development of epidermolysis bullosa acquisita
We report the case of an infant born with perioral vesicles that rapidly spread to involve his mouth and the majority of his body. Histopathology, immunofluorescence, and enzyme‐linked immunohistochemistry assays confirmed a diagnosis of epidermolysis bullosa acquisita (EBA). His mother had no history of EBA, and serum indirect immunofluorescence was negative. The patient improved rapidly with local wound care and oral dapsone.
- 9 February 2018
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 43 (4) , 494-496
Erythema elevatum diutinum-like vasculitis secondary to cocaine adulterated with levamisole
- 9 February 2018
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 43 (4) , 494-496
Erythema elevatum diutinum-like vasculitis secondary to cocaine adulterated with levamisole
- 1 June 2017
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 39 (6) , e71-e72
A Rapidly Growing Facial Mass: Answer
- 1 June 2017
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 39 (6) , e71-e72
A Rapidly Growing Facial Mass: Answer
- 1 June 2017
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 39 (6) , 457-458
A Rapidly Growing Facial Mass: Challenge
- 1 June 2017
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 39 (6) , 457-458
A Rapidly Growing Facial Mass: Challenge
- 28 September 2015
- Published by Wiley in Clinical and Experimental Dermatology
- Vol. 41 (3) , 328-330
Chronic, dusky, indurated plaques on the legs of a 31-year-old woman
- 28 September 2015
- Published by Wiley in Clinical and Experimental Dermatology
- Vol. 41 (3) , 328-330
Chronic, dusky, indurated plaques on the legs of a 31-year-old woman